Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer

L. Pusztai, K. M. Nealy, P. Pallansch, E. Rivera, V. Valero, M. Cristofanilli, G. N. Hortobagyi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint Dive into the research topics of 'Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences